 SHANGHAI and SAN FRANCISCO, May 28, 2021 GLOBE NEWSWIRE -- Zai Lab Limited NASDAQ: ZLAB; HKEX: 9688, an innovative commercial-stage biopharmaceutical company today announced dosing of the first patient in China in the registrational Phase 2 portion of TRIDENT-1 study of repotrectinib being conducted by its partner Turning Point Therapeutics, Inc. and Zai Lab in patients with ROS1 advanced non-small cell lung cancer NSCLC and NTRK advanced solid tumors. Zai Lab has an exclusive license agreement with Turning Point for the development and commercialization of repotrectinib in Greater China mainland China, Hong Kong, Macau, and Taiwan. 